Aproteasome-p27 system is involved in growth inhibition by PPARγ ligands in GI cancers
Aproteasome-p27 system is involved in growth inhibition by PPARγ ligands in GI cancers
批准号:
14570438
负责人:
OKUMURA Toshikatsu
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We have demonstrated that peroxisome proliferator activated receptor gamma(PPARr) ligands inhibit cell growth in gastric and pancreatic cancer cells and that p27 accumulation is essential for the growth inhibition by PPAR ligands(Takahashi et al., FEBS Lett 1999,Motomura et al., Cancer Res 2000). In the present study, we tried to clarify the precise mechanisms by which PPAR ligand stimulates the protein expression of p27. Troglitazone, a ligand for PPAR, increased the protein amount of p27 and inhibited cell growth in gastric, pancreatic and hepatic cancer cells. Lactacystin, an proteasome inhibitor, by itself similarly inhibited cell growth and increased p27 protein expression. Troglitazone potently inhibited proteasome activity. These results suggest that PPAR activation by troglitazone inhibits proteasome activity, thereby accumulating p27 protein, which in turn inhibits cell growth. We furthermore demonstrated that troglitazone suppressed skp2, an ubiqutin ligaze, expression. All these results suggest that the growth inhibition by PPAR actibvation was mediated by p27^<Kip1> accumulation which is induced by both inhibition of ubiquitylation of p27^<Kip1> and reduction of degradation activity of p27^<Kip1> by proteasome.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Takeuchi et al.: "Troglitazone induces G1 arrest by p27Kip1 induction that is mediated by inhibition of proteasome in human gastric cancer cells"Japanese Journal of Cancer Research. 93. 774-782 (2002)
Takeuchi 等人:“曲格列酮通过抑制人胃癌细胞中蛋白酶体介导的 p27Kip1 诱导来诱导 G1 停滞”《日本癌症研究杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nagamine M: "PPARr ligand-induced apoptosis through a p53 dependent mechanism in human gastric cancer cell"Cancer Sci. 94. 338-343 (2003)
Nagamine M:“人胃癌细胞中 PPARr 配体通过 p53 依赖性机制诱导细胞凋亡”Cancer Sci。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Motomura W: "Growth arrest by troglitazone is mediated by p27^<Kip1> accumulation which is resulted from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells"Int J Cancer. 108. 41-46 (2004)
Motomura W:“曲格列酮的生长停滞是由 p27^<Kip1> 积累介导的,这是人肝细胞癌细胞中蛋白酶体活性和 Skp2 表达的双重抑制造成的”Int J Cancer。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nagamine et al.: "PPARr ligand-induced apoptosis through a p53 dependent mechanism in human gastric cancer cell"Cancer Sci. (in press). (2003)
Nagamine 等人:“人胃癌细胞中 PPARr 配体通过 p53 依赖性机制诱导细胞凋亡”Cancer Sci。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Takeuchi S: "Troglitazone induces G1 arrest by p27Kip1 induction that is mediated by inhibition of proteasome in human gastric cancer cells"Jpn J Cancer Res. 93. 774-782 (2002)
Takeuchi S:“曲格列酮通过 p27Kip1 诱导来诱导 G1 停滞,p27Kip1 是通过抑制人胃癌细胞中的蛋白酶体介导的”Jpn J Cancer Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 6 条
Anti-tumor action by PPARgamma ligands in pancreatic cancer: analysis of angigenesis-related genes expression
-
批准号:22590753
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2010
-
负责人:OKUMURA Toshikatsu
-
依托单位:
Molecular mechanism of the PPARγ ligand-induced growth arrest in GI cancers
-
批准号:18590666
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.49万
-
财政年份:2006
-
负责人:OKUMURA Toshikatsu
-
依托单位:
Inhibition of cell growth and cell invasion by PPAR gamma in GI cancers
-
批准号:16590568
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2004
-
负责人:OKUMURA Toshikatsu
-
依托单位:
Role of a novel neurppeptide, orexin,in the central regulation of gastric acid secretion
-
批准号:11670471
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1999
-
负责人:OKUMURA Toshikatsu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
-
批准号:82372743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈卓佳
-
依托单位:
脊髓电刺激活化Na(V)1.1阳性GABA神经元持续缓解癌痛
-
批准号:82371223
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:闻大翔
-
依托单位:
丁酸梭菌代谢物(如丁酸、苯乳酸)通过MYC-TYMS信号轴影响结直肠癌化疗敏感性的效应及其机制研究
-
批准号:82373139
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:李孟鸿
-
依托单位:
均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
-
批准号:82372089
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:李万万
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
-
批准号:82371997
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张春富
-
依托单位:
BRPF1 m6A修饰异常通过重塑BCAT1超级增强子介导Setd2缺陷型肾癌支链氨基酸代谢成瘾的机制研究
-
批准号:82372724
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:何竑超
-
依托单位:
基于影像代谢重塑可视化的延胡索酸水合酶缺陷型肾癌危险性分层模型的研究
-
批准号:82371912
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:吴广宇
-
依托单位:
EGFR通过激活β-catenin重塑肿瘤微环境代谢调控肿瘤免疫逃逸的分子机制研究
-
批准号:32100574
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:邵飞
-
依托单位:
脯氨酸羟化酶EglN1转位到线粒体介导乳腺癌细胞适应缺氧应激的机制研究
-
批准号:32100570
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:闫朝君
-
依托单位: